IQVIA (NYSE:IQV) Coverage Initiated at BMO Capital Markets

Equities researchers at BMO Capital Markets began coverage on shares of IQVIA (NYSE:IQV) in a research report issued on Thursday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $260.00 price target on the medical research company’s stock. BMO Capital Markets’ target price suggests a potential upside of 17.61% from the company’s previous close.

IQV has been the subject of a number of other reports. Robert W. Baird set a $258.00 price objective on IQVIA and gave the stock an “outperform” rating in a research report on Wednesday, October 29th. Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. UBS Group increased their price objective on shares of IQVIA from $225.00 to $250.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and boosted their target price for the company from $195.00 to $235.00 in a report on Thursday, October 9th. Finally, Barclays increased their price target on IQVIA from $185.00 to $200.00 and gave the stock an “equal weight” rating in a report on Thursday, October 2nd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $241.00.

IQVIA Price Performance

IQV stock opened at $221.06 on Thursday. The company has a market capitalization of $37.65 billion, a P/E ratio of 30.32, a PEG ratio of 2.50 and a beta of 1.34. The company has a fifty day moving average price of $202.72 and a 200-day moving average price of $178.54. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. IQVIA has a 52-week low of $134.65 and a 52-week high of $228.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. IQVIA’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities analysts expect that IQVIA will post 10.84 EPS for the current year.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider owned 27,108 shares in the company, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On IQVIA

A number of large investors have recently modified their holdings of the company. Brighton Jones LLC lifted its stake in shares of IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after buying an additional 2,537 shares in the last quarter. Ballentine Partners LLC lifted its position in IQVIA by 4.9% in the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company’s stock valued at $260,000 after acquiring an additional 69 shares in the last quarter. Mutual of America Capital Management LLC increased its holdings in IQVIA by 7.5% during the 1st quarter. Mutual of America Capital Management LLC now owns 34,435 shares of the medical research company’s stock worth $6,071,000 after purchasing an additional 2,405 shares in the last quarter. New York State Common Retirement Fund raised its stake in shares of IQVIA by 1.9% in the first quarter. New York State Common Retirement Fund now owns 104,480 shares of the medical research company’s stock worth $18,420,000 after purchasing an additional 1,958 shares during the last quarter. Finally, CWM LLC lifted its holdings in shares of IQVIA by 4.0% in the first quarter. CWM LLC now owns 12,039 shares of the medical research company’s stock valued at $2,122,000 after purchasing an additional 460 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.